

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 September 2005 (09.09.2005)

PCT

(10) International Publication Number  
**WO 2005/082458 A1**

(51) International Patent Classification<sup>7</sup>: **A61P 35/00**,  
A61K 31/711, 31/7105, 31/713, 31/37, 31/565

**CANCER INSTITUTE, INC.** [US/US]; 44 Binney  
Street, Boston, MA 02115 (US).

(21) International Application Number:  
PCT/US2005/005508

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **KUFE, Donald, W.**  
[US/US]; 179 Grove Street, Wellesley, MA 02181 (US).  
**KHARBANDA, Surender** [US/US]; 8 Jacqueline Circle,  
Natick, MA 01760 (US).

(22) International Filing Date: 22 February 2005 (22.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/547,010 23 February 2004 (23.02.2004) US

(74) Agent: **MOLONEY, Steven, J.**; Fulbright & Jaworski,  
LLP, Suite 2400, 600 Congress Avenue, Austin, TX 78701  
(US).

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:

US 60/547,010 (CON)  
Filed on 23 February 2004 (23.02.2004)


(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN,  
YU, ZA, ZM, ZW.

(71) Applicants (*for all designated States except US*): **ILEX  
PRODUCTS, INC.** [US/US]; 4545 Horizon Hill Blvd.,  
San Antonio, TX 78229-2263 (US). **DANA-FARBER**

[Continued on next page]

(54) Title: MUC1 ANTAGONIST ENHANCEMENT OF DEATH RECEPTOR LIGAND-INDUCED APOPTOSIS

(57) Abstract: The present invention relates to  
methods of enhancing death receptor-induced  
apoptosis in MUC1 expressing cells comprising  
contacting the MUC1 expressing cells with an  
effective amount of a MUC1 antagonist.



WO 2005/082458 A1



**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *with international search report*